New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

about

Cell Type-Specific Mechanisms in the Pathogenesis of Ischemic Stroke: The Role of Apoptosis Signal-Regulating Kinase 1.

P2860

Q54111091-3639948A-44D2-48FE-A4BA-CEC310E8D516

P2860

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

Item

http://www.wikidata.org/entity/Q39213540

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@en

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@nl

type

Item

label

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@en

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@nl

prefLabel

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@en

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@nl

P1476

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

@en

P2093

Hye Sun Gwak

http://www.w3.org/2001/XMLSchema#string

Joo Hee Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

The evolution of anticoagulant therapy

Novel antidotes for target specific oral anticoagulants

Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates

The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran

The epidemiology of venous thromboembolism

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

Bleeding risks of antithrombotic therapy

P304

461-470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4062/BIOMOLTHER.2016.271

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kyung-Min Lim

P577

2017-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28365976

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism

anticoagulation

P932

5590789

http://www.w3.org/2001/XMLSchema#string

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

about

P2860

P2860

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932